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ABSTRACT: The first asymmetric total synthesis of three structures proposed for mycobacterial diacyl trehaloses, DAT1, DAT2,
and DAT3 is reported. The presence of two of these glycolipids, DAT1 and DAT3, within different strains of pathogenic M.
tuberculosis was confirmed, and it was shown that their abundance varies significantly. In mass spectrometry, synthetic DAT2
possessed almost identical fragmentation patterns to presumptive DAT2 from Mycobacterium tuberculosis H37Rv, but did not coelute
by HPLC, raising questions as the precise relationship of the synthetic and natural materials. The synthetic DATs were examined as
agonists for signaling by the C-type lectin, Mincle. The small differences in the chemical structure of the lipidic parts of DAT1,
DAT2, and DAT3 led to drastic differences of Mincle binding and activation, with DAT3 showing similar potency as the known
Mincle agonist trehalose dimycolate (TDM). In the future, DAT3 could serve as basis for the design of vaccine adjuvants with
simplified chemical structure.
■ INTRODUCTION
Mycobacterium tuberculosis (Mtb), which is the causative agent
of the disease tuberculosis (Tb), is responsible for the largest
number of deaths worldwide by a single pathogen, killing an
estimated 1.3 million people annually. The ability of Mtb to
survive and persist in the host is estimated to result in billions
of latently infected individuals worldwide, with a high
incidence of undiagnosed cases.1 After infection of macro-
phages, Mtb is able to survive and replicate in host
phagosomes, while withstanding the hostile acidic environ-
ment. The mycobacterial cell envelope is one factor that
contributes to the resilience of Mtb within host cells.2 It is a
multilayered barrier, composed of many complex lipids,
glycolipids, and glycoproteins, many of which are unique to
Mtb.3−5 In the last decades, it has been shown that many of
these cell wall components have antigenic properties and/or
possess immunomodulatory functions. One class of these
mycobacterial cell wall components, which consists of
diacylated and polyacylated trehaloses, is suggested to be
located on the outer part of the mycobacterial cell wall.6 These
trehalose-based glycolipids are esterified with palmitic or
stearic acid at the 2- and 2′-position, as well as with the Mtb-
specific multimethyl-branched acyl residues phthioceranic acid,
hydroxyphthioceranic acid, mycosanoic acid, mycolipanolic
acid, and mycolipenic acid. Important examples are
Ac2SGL,7−9 Sulfolipid-1,10−12 trehalose monomycolate and
dimycolate,13,14 diacyl trehaloses (DAT),15−17 and pentaacyl
trehaloses (PAT).15,18 Because of the chemical diversity of
DAT and the potential for contamination of even small
amounts of bioactive molecular variants, testing natural DAT
compounds on cells for immune response is not reliable. To
establish the molecular structure of these compounds and
enable further biological studies, several of the compounds
have been the target of total synthesis. In DAT and PAT, both
of which have escaped total synthesis until now, the trehalose
core is acylated with the methyl-branched fatty acids
mycosanoic acid, mycolipanolic acid, and mycolipenic acid
(see Figure 1).17,18
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DAT was first isolated in 1989 by Daffe ́ et al. and was
initially named SL-IV (Sulfolipid-IV), since the structure was
first assigned as 2,3-diacyl-trehalose-2′-sulfate.15,16 The struc-
ture of this family of acyl trehaloses was eventually revisited
and corrected to be 2,3-diacyl-trehalose, and depending on the
nature of the 3-O-acyl group, were termed DAT1, DAT2, or
DAT3 (see Figure 1A). In the following reports, these
compounds were often referenced as just DAT, presenting a
family of mycobacterial glycolipids rather than defined
molecular structures.17 Many studies have asserted the
antigenic properties of DAT glycolipids by ELISA, but these
were tested mainly as mixtures rather than pure compounds. It
was demonstrated multiple times that anti-DAT antibodies are
present in blood sera of Tb patients but not of healthy
controls.17,19−22 This raised great interest in using DAT for the
detection and diagnosis of Tb in patients. The reports utilizing
ELISA for the detection of anti-DAT antibodies, however,
showed a huge variation in sensitivity and specificity,
depending on assay design.23
In recent years, research has focused on elucidating the
biosynthesis of DAT and unravelling its effect on the immune
system.24−27 It was shown that DAT partially inhibits the
proliferation of murine T-cells, suggesting a role in
immunosuppression and T-cell hyporesponsiveness associated
with Tb.28 Mtb mutants incapable of synthesizing mycolipenic
acid, and therefore deficient in DAT and PAT, show
aggregation in liquid culture, because of defects in capsule
attachment, indicating that one of the functions of DAT and
PAT is anchoring the hydrophilic capsule to the hydrophobic
mycolic acid layer of the mycobacterial cell envelope.24,29−31
However, in aerosol infection mouse models using DAT/PAT-
deficient mutants, there were no observed differences in
growth, compared to wild-type compounds, suggesting that
DAT/PAT itself is not necessary for Mtb survival.29
Recently, Mtb cell wall componentssuch as trehalose
dimycolate (TDM, also known as cord factor)have been
identified as high-affinity ligands for macrophage-inducible C-
type lectin (Mincle).32−34 The activation of Mincle results in
downstream expression of cytokines, chemokines, and growth
factors and leads to recruitment of inflammatory cells to the
site of activation as a central part of the innate immune
response to Mtb.33 Several other Mtb cell wall glycolipids have
been identified as Mincle activators,34,35 and there is growing
interest in using these Mincle ligands for the development of
novel vaccine adjuvants.36
In 2017, it was demonstrated that a DAT-containing extract
from Mtb also activated Mincle.35 We realized that, apart from
minute amounts of contaminants in natural isolates that can
influence the results, the activation of Mincle could very well
be dependent on the precise structure of the DAT. Therefore,
we sought to synthesize three different DATs with precisely
defined molecular structure and stereochemistry to study their
Mincle activating properties and to assess the influence of the
acyl substituents on Mincle binding. Furthermore, we aimed to
confirm the presence of these three DATs in different strains of
Mtb, including clinical isolates.
Figure 1. (A) Chemical structures of the mycobacterial diacyl
trehaloses DAT1, DAT2, and DAT3. (B) Retrosynthetic analysis.
Scheme 1. Asymmetric Synthesis of Mycosanic Acid (2), Mycolipanolic Acid (3), and Mycolipenic Acid (4)
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■ RESULTS AND DISCUSSION
Synthesis. DAT1, DAT2, and DAT3 differ in their chiral
acyl group esterified with the 3-OH of the trehalose core.
Therefore, our synthesis plan involved the preparation of
suitably protected 2-palmitoyl trehalose 1 and the three
mycobacterial lipids 2, 3, and 4 as key intermediates necessary
to construct the target diacyl trehaloses. Trehalose 1 could be
obtained starting from α,α-trehalose by a desymmetrization
approach previously applied in the synthesis of trehalose-based
sulfoglycolipids.37,38 The mycobacterial lipids, on the other
hand, can be traced back to the common precursor 5 (Figure
1B). The synthesis of mycolipanolic and mycolipenic acid was
previously reported by us and involves copper-catalyzed
asymmetric conjugate addition (Cu-cat. ACA) and an Evans’
aldol reaction to introduce the stereocenters.39 We sought to
improve the current synthetic procedures to arrive at an
efficient, high-yielding total synthesis.
The synthesis of the chiral enantiopure lipids 2, 3, and 4 (see
Scheme 1) commenced with Cu-cat. ACA of methylmagne-
sium bromide to α,β-unsaturated thioester 5 giving 6 in 81%
yield and 98% enantiomeric excess (ee). Reduction to the
corresponding aldehyde, followed by Horner−Wadsworth−
Emmons reaction, produced another α,β-unsaturated thioester
7. The second methyl stereocenter was again introduced by
Cu-cat. ACA in excellent yield and diastereomeric ratio (dr).
Double DIBAL-H reduction, followed by tosylation, gave 9 in
88% yield over three steps. Tosylate 9 was subjected to a
Grignard cross-coupling in the presence copper(I) to install
the linear alkyl tail of 10. Removal of the silyl protecting group,
followed by Dess-Martin oxidation, gave aldehyde 11 in an
excellent yield of 97% over two steps. From 11, all three
mycobacterial lipids could be synthesized in a limited number
of steps. Mycosanoic acid 2 was obtained in 92% yield after
Pinnick oxidation of aldehyde 11. Mycolipenic acid 4 was
prepared by first subjecting 11 to a Wittig reaction, followed by
alkaline ester hydrolysis. To install the two remaining
stereocenters present in 3, an Evans’ aldol reaction was
performed, giving 13 in good yield and excellent dr. The aldol
product 13 was finally hydrolyzed to give mycolipanolic acid 3.
Compared to the previous syntheses of 3 and 4, the yields
could be significantly improved by careful optimization of the
reactions. For mycosanoic acid, mycolipanolic acid, and
mycolipenic acid, excellent overall yields were obtained with
53% over 10 steps, 47% (previously 2%) over 11 steps, and
46% (previously 5%) over 11 steps, respectively, making the
synthesis of these chiral lipids highly efficient. In the synthesis
of mycolipenic acid, oxidation, Wittig reaction, and ester
hydrolysis were significantly improved, whereas in the case of
mycolipanolic acid, the Evans’ aldol reaction and the removal
of the chiral auxiliary were optimized to give high yields.39
With the enantiopure acids 2−4 in hand, the esterification of
palmitoylated trehalose 1 was achieved by following the
Yamaguchi procedure. In the case of mycosanoic acid and
mycolipenic acid, the corresponding diacylated products were
obtained in good yields; however, in order to reach that result
for mycolipanolic acid, the esterification procedure needed to
be carefully optimized to avoid acyl migration and elimination
of the β-hydroxyl of 3. By limiting the number of equivalents of
base and keeping the time for acid activation at a minimum,
synthesis of 14b could achieved in good yield. Notably, in the
case of 14a and 14c, no acyl migration was observed,
indicating that the β-hydroxyl in 3 might play a role in acyl
migration. Removal of the silyl protecting group of 14a−14c
under buffered conditions gave the corresponding diols 15a−
15c in good to excellent yields. The final deprotectionthe
removal of the benzylidene protecting groupwas achieved by
applying a procedure that was reported by Guiard et al.,37
using aqueous sulfuric acid (DAT1 and DAT3) or by palladium
hydrogenolysis (DAT2, to prevent β-hydroxyl elimination) and
provided the three di-O-acyl trehaloses DAT1, DAT2, and
DAT3 in moderate to good yields. (See Scheme 2.) The
spectral data of DAT1 matched the reported NMR data of
isolated DAT1a.
17 Besra’s report describes the 1H NMR signals
of the anomeric protons of DAT1 at 5.25 and 5.05 ppm for the
acylated and nonacylated glucose unit, respectively. The
spectrum of synthetic DAT1 shows these two anomeric signals
at 5.24 and 5.06 ppm, which is in good agreement.
Furthermore, H-2 and H-3 (at the positions bearing the acyl
moieties) in natural DAT1 appear at 4.83 and 5.40 ppm,
respectively, and in synthetic DAT1 at 4.82 and 5.39 ppm,
respectively. The 13C signals of the anomeric carbons in natural
DAT1 are reported at 95.0 and 92.0 ppm. In the synthetic
material, these signals can be found 94.6 and 91.7 ppm, again
in good agreement. In addition, the carbonyl carbon signals in
synthetic DAT1 resonate at 173.5 and 177.6 ppm and the
corresponding signals in natural DAT1 can be found at 173.8
and 177.8 ppm. All in all, these data leave us confident that the
structure of synthetic DAT1 is identical to that of natural
DAT1, as described by Besra (for more detailed NMR signal
comparison, see the Supporting Information). As for synthetic
DAT2 and DAT3, the structural identity is beyond reasonable
doubt, because the structures of the lipid components have
been previously established39 and the nuclear magnetic
resonance (1H NMR and 13C NMR) and mass spectra showed
patterns very similar to those of synthetic and natural DAT1.
Detection of DAT1, DAT2, and DAT3 in Mtb Strains.
Having completed the total synthesis of DAT1, DAT2, and
DAT3 with structures as described in the literature,
17 we
sought to determine if the synthesized glycolipids match the
structures of natural products present in virulent strains ofMtb.
Mycobacterial lipid extracts of the reference strain H37Rv and
three clinical isolates j257, j011, and j117 were analyzed by
Scheme 2. Completion of the Total Synthesis of the
Mycobacterial Glycolipids DAT1, DAT2, and DAT3
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means of LC-MS. The extracted-ion chromatograms (Figure
2A) suggest that all three DATs are produced by the laboratory
strain H37Rv. Ions consistent with DAT1 and DAT2 were only
reliably detected in the H37Rv strain, whereas DAT3 could be
detected in all four strains. The corresponding mass spectra of
the detected natural DATs matched the calculated m/z of each
compound within the expected experimental error of 3−4
ppm. Collision-induced fragmentation (see the data given in
the Supporting Information) of the natural and synthetic
DATs yielded interpretable cleavages (Figure 2C, H-transfers
not shown) that supported the general structures and
connectivity. Co-injection (Figure 2B) of synthetic standards
and natural lipid mixtures showed a chromatographic match
for DAT1 and DAT3. However, synthetic DAT2 eluted more
than a minute earlier than the natural compound. Thus,
whereas the identity of DAT1 and DAT3 can be considered to
have been established beyond a reasonable doubt, we conclude
that material with the structure of synthetic DAT2 does not
occur in the H37Rv strain. This may mean that an isomer of
the proposed structure of DAT2 is present in this strain, or that
the structure of natural DAT2 has been incorrectly assigned.
15
Mincle Activation by DAT1, DAT2, and DAT3. We
decided to assess the Mincle activating properties of the
synthetic DATs as well (see Figure 3), keeping in mind that
our synthetic DAT2 was not present in the studied Mtb strains.
Mincle activation was compared to the known Mincle-agonist
TDM, which is highly potent. Previous studies have identified
various lipidlike trehaloses that activate Mincle, so we expected
that all three forms of DAT, which differ in small ways in their
alkyl chains, were good candidate activators. Prior to the
functional assays, TLC analysis of synthetic DAT1, DAT2, and
DAT3 was performed to exclude the presence of glycolipid
degradation products and quantification errors (Figure 3A).
Mincle activation requires the adaptor protein FcRγ. There-
fore, functional Mincle-activation assays were performed by
treatment of NFAT-GFP reporter cells expressing murine
Mincle and FcRγ (Figure 3B) or human Mincle and FcRγ
(Figure 3C) with the synthetic DAT variants and TDM. In
both assays, DAT3 was able to activate Mincle. In the case of
human Mincle, DAT3 showed similar potency to the highly
potent agonist TDM. DAT2 and, remarkably, DAT1 only
weakly activated murine Mincle. When using human Mincle-
expressing cells, DAT2 showed moderate activation, whereas
DAT1 again barely induced Mincle stimulation. In an
independent experiment, an ELISA-based technique was
applied that was dependent not on cellular activation but
only on the detection of physical interaction between DAT and
soluble Mincle proteins (Figure 3D). Strong binding of murine
Mincle to DAT3 was observed, but only minimal binding to
DAT1 and DAT2, thereby confirming the results obtained in
the cellular activation assay. These results provide evidence
that the chemical structure of the 3-O-acyl substituent (either
mycosanoic acid, mycolipanolic acid, or mycolipenic acid)
strongly influences Mincle binding and activation.
■ CONCLUSIONS
In this study, we have accomplished the first total synthesis of
three structurally related mycobacterial DATs. These synthetic
DATs were used as a reference in the detection of natural
DATs in Mtb by liquid chromatography-mass spectroscopy.
This showed that the presence and abundance of DAT1 and
DAT3 differs strongly, dependent on the Mtb strain. This has
important consequences for the potential use of DATs as
Figure 2. Detection of DAT variants in M. tuberculosis strains. Lipid
extracts from four different M. tuberculosis strains were analyzed via
high-performance liquid chromatography−mass spectroscopy
(HPLC-MS): laboratory strain H37Rv, and three clinical isolates
named j257, j011, and j117. Extracted ion chromatograms of ions
corresponding with the ammonium adduct of DAT1 (calculated m/z
= 948.733), DAT2 (m/z = 1006.775), and DAT3 (m/z = 988.764)
showed m/z values consistent with those expected from DATs. (B)
Comparison with synthetic standards showed chromatographic
coelution for DAT1 and DAT3 but not for DAT2, indicating that
synthetic DAT2 is not identical to natural DAT2. (C) CID analysis of
the standards and natural compounds (see data given in the
Supporting Information) yielded fragmentation patterns diagnostic
for the known structures.
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markers for Tb infection. In addition, it might explain a
posteriori the irreproducibility observed in the many attempts
to reliably detect DAT by ELISA. It also showed that the
proposed structure of DAT2 does not occur in the studied
strains, including the H37Rv strain. An alternative explanation
is that the structure of DAT2 has been assigned incorrectly,
since, because of the lack of literature NMR data, a comparison
with our synthetic material was not possible. This will be
further investigated.
We found that small changes in the structure of the
branched acyl chain in DAT lead to large differences in
recognition by Mincle. It has been shown previously by Decout
et al. that one of the molecular requirements for Mincle
recognition, besides the trehalose or glucose scaffold, is the
presence of two alkyl chains, either as two separate esters or as
one fatty acid ester with an alkyl chain branched α to the
carbonyl. Moreover, it was previously demonstrated that the
lipid chains can be significantly shorter than the C80 lipids
present in TDM. For instance, the synthetic Mincle ligand
GlcC14C18, a glucose esterified at the 6-position with a C18
alkyl tail with a C14 alkyl branch on the α-position, shows even
higher potency than TDM.35 In addition, in a previous report,
Mincle activation by β-glucosylceramide, which also contains
an unsaturation in the lipid chain, was demonstrated.40 Here,
we show that the presence of the α,β-unsaturation in DAT3
enhances Mincle activation drastically, compared to the
saturated counterpart DAT1. This leads us to speculate that
the double bond either serves as a point of interaction (such as
π−π-stacking) with parts of the Mincle binding pocket or
induces a specific conformation beneficial for binding. All in
all, one might conclude that DAT3 could be an alternative
starting point for adjuvant design for TDM, given the higher
complexity and lipophilicity of the latter. For future develop-
ment of Mtb vaccine adjuvants, even simpler DAT analogues
could be designed without chiral methyl branches or based on
glycose rather than trehalose.
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